Related Experiment Video
Updated: Aug 21, 2026
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory
Nicolas Tchitchek1, Michelle Rosenzwajg2, Roberta Lorenzon2
1Sorbonne Université, Inserm, UMRS 959, Immunology-Immunopathology-Immunotherapy (i3), Paris, France.
Objectives:
Low-dose interleukin-2 (IL-2LD) preferentially stimulates regulatory T cells (Treg) over conventional CD4+ T cells (Tconv), controlling inflammation and promoting immune tolerance in autoimmune and other immune-mediated inflammatory diseases. However, IL-2 has pleiotropic functions, and its therapeutic mechanisms of action remain incompletely defined. In addition, the absence of reliable biomarkers of clinical efficacy limits personalised treatment strategies. We therefore aimed to characterise the transcriptomic effects of IL-2LD in Treg and Tconv cells and to identify candidate biomarkers associated with clinical response.
Methods:
We analysed the whole transcriptome of purified Treg and Tconv from 23 patients with various immune-mediated inflammatory diseases, predominantly autoimmune disorders, treated with IL-2LD in the TRANSREG open-label, exploratory basket trial (NCT01988506). Peripheral blood samples were collected at baseline, day 8, and month 3 after the initiation of treatment. Gene network analysis and multivariate modelling were performed to explore underlying immunological mechanisms of clinical efficacy and evaluate candidate biomarkers associated with clinical response.
Results:
IL-2LD induced broad immune transcriptomic changes, predominantly in Treg cells. Beyond expected IL-2-related gene activation, treatment was associated with progressive downregulation of interferon-stimulated genes (ISGs) in both Treg and Tconv cells, including GBP1, IFIT2, IFIT3, and RSAD2. Importantly, a multivariate model based on baseline ISG expression showed promise for predicting clinical response status to IL-2LD.
Conclusions:
These findings demonstrate that IL-2LD not only expands and activates Treg cells but also shapes an anti-inflammatory transcriptomic landscape characterised by ISG downregulation in Treg and Tconv cells. Baseline ISG expression was associated with treatment response, supporting its evaluation as a candidate biomarker for IL-2LD therapy.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:28Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...